Out in @JACCJournals we use NIH RePORTER to show: ▫️ women were awarded only 20% of R01 grants in CV research from 2011-2020 ▫️women are more likely to receive less funding $ ▫️# of grants and funding $ increased among both men and women in CV research https://t.co/rlCn0qucLf

Join our team in NOLA at #AHA25 this weekend to explore our latest work on cardiovascular prevention, SDOH, digital health, environmental health & radiomics. @HMethodistCV @Sadeer_AlKindi @khurramn1

Thrilled and honored to be a part of this years cohort! Extremely grateful to @khurramn1 & @Sadeer_AlKindi for their mentorship, and to our wonderful team at @HMethodistCV @C3PH_HM

Excited to participate in #AHA25 where our collaborative team will present/contribute to >25 presentations in interconnected disciplines #EnvironmentalHealth #DigitalHeatlh #Radiomics #Imaging #AI #SDoH @HMethodistCV @khurramn1

Session 3 Wrap-Up – Obesity and Weight Management in HF We just concluded Session 3 of #eSPACEHF2025, chaired by Prof. Anu Lala-Trindade and Dr. @matthewmylee Dr. Shahzeb Khan highlighted how longer exposure to obesity dramatically increases HF risk, with up to 90% developing

We are live with Session 3 of the plenary at #eSPACEHF2025, chaired by @dranulala and @matthewmylee @ShahzebKhanMD has just finished his presentation on Converging Epidemics – Obesity & Heart Failure, sharing insights on adult obesity prevalence, projected trends, and the

Congratulations to @GarimaVSharmaMD @NanditaScottMD & @sarma_amy on a great inaugural event! Was a pleasure to share the space with some brilliant physician-scientists from across the US.

Honored to present and receive an Hon. Mention at the MGB/Inova Young Investigators Award in Women’s CVH for our work on environmental vulnerability and CV risk in women. Grateful to Drs @Sadeer_AlKindi @khurramn1 for their mentorship and to our amazing team at @C3PH_HM 🙏🏻

Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum benefits of early up-front initiation of quadruple medical therapy for HFrEF, rapid initiation of SGLT2i for HF regardless of EF https://t.co/xtsYeyoC4l

Happy to present our abstract on the importance of multimodality imaging in the evaluation and management of paravalvular leaks post-TAVR at #ACC2025. Grateful for all the opportunities and support @WilliamZoghbi, and proud to be part of the @HMethodistCV team!

Thrilled to have presented my poster on T-TEER in Orthotopic Heart Transplant Recipients at #ACC2025! @HMethodistCV @SachinGoelMD

Excited to share our article on Obesity and Atherosclerotic Cardiovascular Disease: A Review of Social and Biobehavioral Pathways https://t.co/R7EJljAVuB Grateful for @IzzaShahid_'s mentorship!

CVD in women has unique challenges and risk factors needing gender-specific primary prevention strategies. Primary Prevention of CVD in Women - Izza Shahid, Eleonora Avenatti @AnoopTitus @Sadeer_AlKindi @KhurramN1 Earn free CME! #DeBakeyCVJournal https://t.co/zIx3KSWqUq

Dr. Izza Shahid unveils a poster at #ACC24 highlighting financial toxicity in individuals eligible for semaglutide within a U.S. representative population with established atherosclerotic cardiovascular disease. #MedicalResearch #Cardiology #ASCVD

Dr. Izza Shahid presents at #ACC24 on cost-related medical non-adherence in semaglutide-eligible U.S. adults with atherosclerotic cardiovascular disease, offering insights for the nationally representative population. #MedicalResearch #Cardiology #ASCVD

Join our team at #ACC24 as we share the latest in CV prevention and cardiometabolic medicine. @khurramn1 @Sadeer_AlKindi @C3PH_HM @HMethodistCV

If you are in Atlanta for #ACC24, join the phenomenal CV prevention team @HMethodistCV as they present their work and share the latest insights in cardiovascular prevention. @khurramn1 @Sadeer_AlKindi

Excited for #ACC24? Visit @NasirLab_HM @HMethodistCV prevention team presentations & share ur feedback -Burden, variability and national/health system impact of CV metabolic risk -CV impact of exposome measurements - Insights on Cardiorhum & novel atheromeasurement in gen pop

Don't delay. Fight clinical inertia. Start 4 pillars in eligible patients. Quickly. Time to consider the "time to #quadtherapy" performance measure for #HFrEF @IzzaShahid_ @gcfmd @DCRINews @JCardFail @JavedButler1 @robmentz @dranulala @AndrewJSauer https://t.co/uMWKc22Nw2

Khan et al, 2020: Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US FDA Approval of Novel Cardiometabolic Drugs @ShahzebKhanMD @safinmc @IzzaShahid_ @haiderwarraich @SJGreene_md @javedbutler1 @ErinMichos https://t.co/pTRxtV4yLo